Drug Profile

APL 9

Alternative Names: APL-9

Latest Information Update: 22 May 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Apellis Pharmaceuticals
Class Antianaemics; Cyclic peptides; Peptides; Polyethylene glycols
Mechanism of Action Complement C3 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

No development reported Immunological disorders; Paroxysmal nocturnal haemoglobinuria
Discontinued SARS-CoV-2 acute respiratory disease

Most Recent Events

14 May 2026 Apellis Pharmaceuticals has been acquired by Biogen
28 Jul 2024 No recent reports of development identified for phase-I development in Immunological-disorders in USA (IV)
02 Jun 2021 Phase-I clinical trials in Immunological disorders in USA (IV) before June 2021 (Apellis Pharmaceuticals pipeline, June 2021)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com